Others were suggested that BIM deletion polymorphism was not significantly correlated with the kinase inhibitor efficacy for EGFR-mutated NSCLC, CML and hepatocellular cancer (HCC) patients20, 21, 22, 23. This evidence concerns the gene BCL2L11 and non-small cell lung carcinoma.